BioNTech SE (BNTX)

COVID-19 Vaccine Demonstrates Strong Immune Response,
High Efficacy and Favorable Safety in Children 6 Months to
Under 5 Years of Age Following Third Dose

https://investors.biontech.de/news-releases/news-release-details/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune

This stock is the perfect choice for the current economic scenario:

- impending recession: irrelevant
- China's economic crisis: irrelevant
- Rising interest rates: irrelevant
- supply chain issues: none
- Economic dangers from Russia's invasion: irrelevant
- energy prices: irrelevant
- consumer sentiment: irrelevant

The following is the summary from the article in below:
“
The immune system involves a host of players, including B cells, which produce antibodies, and T cells, which target infected cells during an infection – and T cells are often part of emerging discussions around vaccine durability.

A study published in the journal Cell in January showed just how much of a role the other parts of the immune system play in the durability of protection following Covid-19 vaccination.

The study found that, among 96 vaccinated adults, even though antibody levels decreased against coronavirus variants, the T cells induced by various types of Covid-19 vaccines – the Moderna, Pfizer/BioNTech, Johnson & Johnson and Novavax vaccines – were able to recognize coronavirus variants, including Omicron, even though the vaccines were developed based on the original coronavirus.

“The important thing for our study was we collected all those samples at the same place with the same techniques and ran all the experiments head-to-head so it was really a fair head-to-head test,” said Shane Crotty, virologist and professor at La Jolla Institute for Immunology, who was an author of the study.

Plus, those vaccines were developed using different technologies. Moderna and Pfizer/BioNTech are mRNA vaccines. Johnson & Johnson is a viral vector vaccine. Novavax, which is not yet authorized for emergency use in the United States, is a protein-based vaccine.

“The mRNA vaccines, both Moderna and Pfizer, generated these four categories: antibodies, memory B cells, helper T cells and killer T cells. Overall, the mRNA vaccines generated the best of all four of those,” Crotty said, adding that among people who were vaccinated with Johnson & Johnson, generally there appeared to be less of all four and Novavax appeared to generate somewhat less memory B cells and significantly less killer T cells.

“So, there were some different mixes there,” Crotty said. “Our immunological data are generally consistent with the vaccine efficacy data that’s out there from the clinical trials and real-world studies that in general, the mRNA vaccines are better than J&J in terms of protection from infection but also protection from hospitalization, with Novavax being somewhere in between, but doing quite well.”

https://www.cell.com/cell/fulltext/S0092-8674(22)00073-3

Todays Numbers - Catching up

102,500,000 –- Received Boosters – Since – August 13th (first reported date)
12.400,000 – Received Second Boosters – One day change – 300,000
56,976,145 - PFE/BNTX – 52,026 –1 Day change
43,995,157 – MRNA – 32,464 – 1 Day Change
1,519,886- J&J – 616 - 1 Day Change
Retention – % Take Same Booster
PFE/BNTX - 93.0% (48.01M); otherwise MRNA
MRNA- 91.8% (35.01M) otherwise PFE/BNTX
J&J- 23.8% (1.35M); otherwise - 41.1% (2.32M) MRNA - 35.0% (1.98) PFE/BNTX
258,074,668 Americans - have received 1 dose – 77.7% of US population
Fully Vaccinated Total
PFE (2 doses) - 126,855,388
MRNA (2 doses) - 76,806,824
J&J (1 dose) - 18,759,463
Doses Distributed to States (Yesterday) – 783,300
PFE Delivered – 433,036,335
MRNA Delivered – 275,224,320
J&J Delivered- 30,834,800
First and Second Doses Administered Yesterday –409,031
Boosters Administered – Yesterday- 78,774
PFE/BNTX administered including boosters 284,206 (PFE/BNTX) vs 197,525 doses for MRNA-
One Day Vaccinations (excludes boosters)
272,702 PFE/BNTX, (of which- 49,873 are second doses)
186,004 MRNA, (of which – 18,642 are second doses)
4,151 J&J First Dose –616 (second dose boosters) Market Share Administered-
Total Administered Excludes Boosters– 582,652,102
BNTX/PFE –59.03%, MRNA –37.74%%, J&J -3.22%

FLU
BNT 161 (Clinical Trial) NCT05052697
A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY,
TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE
AGAINST INFLUENZA IN HEALTHY INDIVIDUALS

Last Update Posted Date May 20, 2022

Actual Study Start Date ICMJE September 13, 2021
Estimated Primary Completion Date January 9, 2023
(Final data collection date for primary outcome measure)

(Updates after panel vote)

By Manas Mishra and Michael Erman

May 19 (Reuters) - An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday voted to recommend COVID-19 vaccine booster shots for children ages 5 to 11, at least five months after completing their primary vaccination course.

The advisers considered data from the CDC that showed protection from two doses starts to wane over time, and that boosters in older age groups improved efficacy against severe COVID and hospitalizations.

CDC Director Rochelle Walensky still needs to sign off on the committee's recommendation, but signaled at the meeting that she was likely to back the additional shots.

"We know immunity wanes over time, and we need to do all we can now to protect those most vulnerable," Dr. Walensky said. "It's important for us to anticipate where this pandemic is moving and deploy the tools we have where they will have the greatest impact."

Just over 29% of U.S. children ages 5-11 are considered fully vaccinated with two doses of the Pfizer/BioNTech shot. The vaccine is not yet authorized for children younger than 5.

The committee voted 11 to 1 to recommend the additional shots, with one doctor abstaining.

Dr. Helen Keipp Talbot was the lone committee member to vote against recommending the boosters, arguing that the focus should be on increasing the vaccination rate in the age group.

"Boosters are great once we've gotten everyone their first round," she said. (Reporting by Manas Mishra in Bengaluru and Michael Erman in New Jersey; Editing by Bill Berkrot)